Catheter Precision Expands Global Footprint with New VIVO Purchase Order in Slovenia
FORT MILL, S.C., January 20, 2026 (GLOBE NEWSWIRE) - Catheter Precision, Inc. (VTAK - NYSE/American), a US-based medical device company specializing in cardiac electrophysiology, has announced a significant advancement in its international presence. The company has received a VIVO purchase order from the University Clinical Center Ljubljana, a leading hospital in Slovenia, marking its entry into the market and expanding its global sales footprint to 15 countries.
Key Details of the Purchase Order
The University Clinical Center Ljubljana is the largest healthcare institution in Slovenia, offering secondary and tertiary healthcare services, along with educational and research functions. This purchase order underscores Catheter Precision’s commitment to broadening its operational reach and enhancing its service offerings in the electrophysiology sector.
Significance of the VIVO System
VIVO, which stands for View Into Ventricular Onset, is a non-invasive 3D imaging system designed to assist medical professionals in identifying the origins of ventricular arrhythmias prior to procedures. This advanced technology effectively streamlines workflows, reduces procedural times, and contributes to improved patient recovery.
- New order from University Clinical Center Ljubljana
- VIVOsystem enhances the identification of arrhythmias
- Reduction in overall procedure time and improved recovery
CEO Commentary on Expansion
David Jenkins, CEO of Catheter Precision, expressed enthusiasm regarding the company’s growth: “We are thrilled that we are growing our global sales footprint and now have products in 15 countries. Continued expansion validates that our products, both VIVO and LockeT, provide benefits to physicians by solving real-world challenges in EP Lab workflows.” Jenkins further emphasized that the products are user-friendly and effective in facilitating electrophysiology procedures.
Future Growth Prospects for Catheter Precision (VTAK)
This recent acquisition is indicative of Catheter Precision's ongoing success, following a year of substantial growth driven by effective navigation of international regulatory landscapes and the formation of robust distribution partnerships. Positioned strategically within the market, Catheter Precision is set to maintain its commercial expansion trajectory into 2026.
About LockeT
LockeT is another innovative product by Catheter Precision, functioning as a suture retention device aimed at improving wound closure after percutaneous venous punctures. This Class 1 device has gained FDA registration and holds CE Mark approval.
About Catheter Precision
Catheter Precision is dedicated to advancing cardiac arrhythmia treatments through innovative medical device solutions. The company continually collaborates with physicians to enhance technology for electrophysiology procedures.
Cautionary Note on Forward-Looking Statements
The information in this article includes forward-looking statements which are subject to risks and uncertainties that may cause actual results to differ. These risks and uncertainties are further elaborated under the caption “Risk Factors” in the Company’s Form 10-K, available at www.sec.gov. The Company assumes no obligation to update any forward-looking statements unless required by law.